backgroundth
ongo
yellow
fever
yf
epidem
angola
strain
global
vaccin
suppli
prompt
adopt
dose
spare
vaccin
campaign
kinshasa
julyaugust
although
fractionaldos
vaccin
similar
standarddos
vaccin
safeti
immunogen
efficaci
untest
urgent
need
ensur
robust
fractionaldos
vaccin
elucid
condit
dose
fraction
would
reduc
transmiss
methodsw
estim
effect
reproduct
number
yf
angola
use
diseas
natur
histori
case
report
data
simpl
mathemat
model
yf
transmiss
calcul
infect
attack
rate
iar
proport
popul
infect
cours
epidem
vari
level
transmiss
fivefold
fractionaldos
vaccin
efficaci
two
vaccin
scenario
random
vaccin
hypothet
popul
complet
suscept
ii
kinshasa
vaccin
campaign
julyaugust
differ
age
cutoff
fractionaldos
vaccin
findingsw
estim
effect
reproduct
number
earli
angola
outbreak
vaccin
action
allornoth
ie
proport
vaccine
receiv
manuscript
version
made
avail
cc
byncnd
licens
correspond
joseph
wu
marc
lipsitch
publish
disclaim
pdf
file
unedit
manuscript
accept
public
servic
custom
provid
earli
version
manuscript
manuscript
undergo
copyedit
typeset
review
result
proof
publish
final
citabl
form
pleas
note
product
process
error
may
discov
could
affect
content
legal
disclaim
appli
journal
pertain
jtw
cmp
ml
review
literatur
design
studi
jtw
ml
develop
mathemat
model
jtw
ran
mathemat
model
jtw
cmp
gml
ml
interpret
model
result
approv
final
version
complet
remaind
receiv
protect
nfold
fraction
dramat
reduc
iar
long
efficaci
exce
benefit
threshold
becom
stringent
vaccin
action
leaki
ie
suscept
vaccine
reduc
factor
equal
vaccin
efficaci
age
cutoff
fractionaldos
vaccin
chosen
kinshasa
vaccin
campaign
name
year
provid
largest
reduct
iar
efficaci
fivefold
fractionaldos
vaccin
exce
interpretationdos
fraction
effect
strategi
reduc
infect
attack
rate
would
robust
larg
margin
error
case
fractionaldos
lower
expect
wu
et
al
yellow
fever
yf
resurg
angola
threaten
spread
countri
rel
low
yf
vaccin
coverag
juli
yf
case
export
angola
kenya
case
china
drc
rais
concern
yf
could
resurg
popul
compet
vector
present
vaccin
coverag
low
inde
drc
alreadi
declar
yf
epidem
kinshasa
two
provinc
broad
band
subsaharan
africa
north
namibia
zambia
risk
http
wwwcdcgovyellowfevermapsafricahtml
much
northern
portion
south
america
http
wwwcdcgovyellowfevermapssouthamericahtml
global
commun
increasingli
concern
risk
yf
emerg
asia
diseas
curious
absent
despit
seemingli
amen
condit
safe
highli
effect
liveattenu
vaccin
yf
howev
global
emerg
stockpil
yf
vaccin
maintain
approxim
million
dose
alreadi
deplet
twice
angola
outbreak
throughput
million
dose
per
month
yf
vaccin
suppli
inadequ
given
larg
urban
popul
risk
yf
infect
respons
shortag
dose
fraction
propos
maxim
public
health
benefit
avail
yf
vaccin
dose
fraction
smaller
amount
antigen
would
use
per
dose
order
increas
number
person
vaccin
given
quantiti
vaccin
strategi
previous
propos
extend
prepandem
influenza
vaccin
suppli
dose
fraction
consist
adopt
equiti
yf
vaccin
access
would
also
enhanc
within
across
countri
risk
peopl
could
benefit
vaccin
without
depriv
other
inde
follow
sage
endors
june
recommend
dose
fraction
emerg
yf
vaccin
campaign
julyaugust
vaccin
million
peopl
kinshasa
million
anterior
angola
million
along
drcangola
corridor
specif
million
standarddos
vaccin
would
alloc
kinshasa
standarddos
vaccin
would
given
children
age
month
year
remain
alloc
fraction
fivefold
administ
rest
popul
evid
base
fractionaldos
yf
vaccin
built
upon
two
studi
compar
safeti
immunogen
standarddos
fivefold
fractionaldos
yf
vaccin
first
random
noninferior
trial
show
ml
intraderm
id
vaccin
yf
vaccin
equal
safe
immunogen
compar
standard
subcutan
vaccin
second
random
trial
subcutan
administr
vaccin
given
brazil
show
signific
differ
immunogen
viremia
kinet
current
administ
vaccin
contain
iu
viru
given
subdos
low
full
dose
iu
even
lower
dose
produc
noninferior
immun
respons
equival
viremia
kinet
comparison
minimum
yf
vaccin
iu
per
dose
end
shelf
life
efficaci
trial
yf
vaccin
howev
ever
perform
human
compar
efficaci
differ
dose
rout
administr
remain
uncertain
particular
known
whether
equal
immunogen
impli
equal
vaccin
efficaci
yf
vaccin
moreov
find
equal
immunogen
reduc
dose
limit
healthi
adult
compar
data
exist
children
thu
age
cutoff
year
fractionaldos
vaccin
kinshasa
elderli
immunocompromis
individu
eg
hivinfect
peopl
pregnant
women
etc
noninferior
immunogen
fractionaldos
vaccin
provid
strong
basi
initi
consider
dosespar
strategi
yf
vaccin
would
prudent
ensur
robust
strategi
care
evalu
risk
epidemiolog
impact
reduc
vaccin
efficaci
fractionaldos
vaccin
evalu
nontrivi
even
dose
fraction
reduc
vaccin
efficaci
higher
vaccin
coverag
may
confer
higher
herd
immun
case
number
infect
could
significantli
reduc
indirect
effect
largescal
vaccin
lower
transmiss
larger
number
infect
avert
indirect
protect
illustr
previou
studi
dose
fraction
prepandem
influenza
vaccin
import
herd
immun
yf
vaccin
unknown
transmiss
yf
urban
set
never
adequ
character
due
limit
data
strengthen
evid
base
public
health
benefit
dose
fraction
yf
vaccin
use
simpl
mathemat
model
assess
potenti
reduct
infect
attack
rate
iar
defin
proport
popul
infect
cours
sustain
epidem
confer
fivefold
dose
fraction
differ
epidem
scenario
reduct
vaccin
efficaci
find
dosespar
strategi
consid
like
provid
signific
benefit
epidemiolog
best
polici
determin
balanc
logist
regulatori
consider
extent
epidemiolog
benefit
particular
conclud
kinshasa
dosespar
vaccin
campaign
julyaugust
would
effect
strategi
reduc
infect
attack
rate
result
would
robust
larg
margin
error
case
fivefold
fractionaldos
efficaci
turn
lower
expect
first
parameter
realist
epidem
scenario
analysi
estim
reproduct
number
yf
cours
angola
outbreak
use
estim
earli
epidem
stage
largescal
vaccin
affect
transmiss
rang
basic
reproduct
number
r
futur
outbreak
popul
end
use
wallinga
teuni
method
estim
reproduct
number
yf
daili
number
confirm
yf
case
record
april
angola
situat
report
assum
case
attribut
local
transmiss
ie
import
case
estim
extrins
incub
period
assum
averag
temperatur
angola
degre
celsiu
outbreak
estim
serial
interv
distribut
make
follow
assumpt
extrins
incub
period
follow
weibul
distribut
estim
ref
mean
day
degre
celsiu
ii
intrins
incub
period
follow
lognorm
distribut
estim
ref
mean
day
iii
infecti
period
human
exponenti
distribut
mean
day
iv
mosquito
lifespan
exponenti
distribut
mean
day
estim
initi
reproduct
number
yf
outbreak
angola
averag
reproduct
number
among
case
develop
symptom
one
serial
interv
vaccin
campaign
began
affect
diseas
transmiss
see
figur
let
proport
popul
suscept
vaccin
campaign
begin
v
vaccin
coverag
achiev
standarddos
vaccin
suppos
standarddos
vaccin
fraction
n
nfold
fractionaldos
vaccin
ie
contain
amount
antigen
standarddos
vaccin
vaccin
efficaci
n
vaccin
efficaci
standarddos
vaccin
assum
given
v
highest
fraction
sensibl
n
max
v
suscept
popul
identifi
target
vaccin
n
max
otherwis
ie
fraction
n
must
lie
n
max
avoid
overst
benefit
dose
fraction
assum
vaccin
efficaci
nfold
fractionaldos
vaccin
n
increas
linearli
amount
antigen
vaccin
see
appendix
explan
potenti
increas
vaccin
wastag
dosespar
would
mostli
due
unus
reconstitut
vaccin
increas
vaccin
failur
due
inexperi
intraderm
administr
among
vaccin
set
mass
vaccin
campaign
wastag
due
unus
vaccin
dose
like
neglig
vaccin
session
larg
use
iar
outcom
measur
evalu
impact
dose
fraction
calcul
iar
use
classic
final
size
approach
exact
directli
transmit
sirtyp
diseas
approxim
vectorborn
diseas
nonetheless
approxim
excel
realist
paramet
rang
small
proport
mosquito
infect
yf
viru
even
epidem
necessit
pool
test
see
appendix
mathemat
detail
denot
iar
nfold
dose
fraction
iar
n
evalu
outcom
fractionaldos
vaccin
standarddos
vaccin
calcul
absolut
rel
reduct
iar
iar
iar
n
iar
n
iar
respect
assum
vaccin
campaign
complet
start
epidem
assum
vaccin
action
allornoth
ie
nfold
fractionaldos
vaccin
provid
protect
infect
proport
n
vaccine
protect
remaind
case
nfold
dose
fraction
result
lower
iar
vaccin
efficaci
nfold
fractionaldos
vaccin
least
time
standarddos
vaccin
ie
n
n
see
appendix
detail
term
benefit
threshold
dose
fraction
also
consid
altern
case
vaccin
action
leaki
ie
nfold
fractionaldos
vaccin
reduc
hazard
infect
probabl
diseas
transmiss
per
mosquito
bite
vaccine
proport
n
compar
allornoth
vaccin
leaki
vaccin
substanti
higher
benefit
threshold
especi
transmiss
high
see
result
howev
yf
vaccin
action
much
like
allornoth
leaki
see
discuss
present
main
result
context
allornoth
vaccin
action
principl
diseas
transmiss
halt
effect
vaccin
coverag
defin
proport
popul
immun
egv
n
n
vaccin
compris
nfold
fractionaldos
vaccin
exce
herd
immun
threshold
consid
two
vaccin
scenario
variou
level
transmiss
efficaci
reduct
fractionaldos
vaccin
random
vaccin
hypothet
popul
illustr
potenti
impact
dose
fraction
first
consid
hypothet
scenario
entir
popul
suscept
individu
probabl
receiv
vaccin
compar
outcom
use
entir
vaccin
stockpil
either
standarddos
fivefold
fractionaldos
vaccin
individu
immun
due
previou
exposur
vaccin
vaccin
target
suscept
individu
result
iar
within
suscept
popul
would
random
vaccin
complet
suscept
popul
coverag
v
basic
reproduct
number
r
kinshasa
vaccin
campaign
julyaugust
popul
size
kinshasa
estim
around
million
http
wwwciagovlibrarypublicationstheworldfactbookgraphicspopul
cgpopgraph
around
million
standarddos
vaccin
expect
administ
kinshasa
popul
vaccin
campaign
person
commun
bruce
aylward
alejandro
costa
dosespar
strategi
standarddos
vaccin
given
children
age
month
year
suffici
vaccin
unvaccin
children
age
rang
remain
alloc
fraction
onefifth
standard
dose
given
rest
popul
compar
outcom
vaccin
administ
standard
dose
strategi
ii
accord
dosespar
strategi
altern
age
cutoff
fractionaldos
vaccin
rang
year
strategi
f
latter
let
z
age
cutoff
p
z
proport
popul
target
standarddos
vaccin
given
standarddos
vaccin
coverag
v
proport
popul
receiv
standarddos
fractionaldos
vaccin
min
v
p
z
max
v
p
z
respect
therefor
effect
vaccin
coverag
vaccin
campaign
b
min
v
p
z
max
v
p
z
b
vaccin
coverag
immedi
campaign
ie
end
june
see
appendix
calcul
detail
sponsor
studi
role
studi
design
data
collect
data
analysi
write
report
decis
publish
author
access
data
correspond
author
final
respons
submit
public
figur
show
initi
reproduct
number
yf
angola
ci
mean
mosquito
lifespan
day
respect
estim
may
reflect
partial
immun
due
prior
vaccin
exposur
among
popul
estim
around
angola
popul
vaccin
yf
epidem
see
appendix
calcul
detail
assum
basic
reproduct
number
futur
outbreak
anoth
popul
would
rang
due
vari
vector
ecolog
level
preexist
immun
popul
fractionaldos
vaccin
substanti
reduc
iar
v
reduct
diminish
insignific
level
v
close
herd
immun
threshold
eg
r
respect
short
dose
fraction
reduc
iar
standarddos
vaccin
suppli
insuffici
halt
diseas
transmiss
ii
fractionaldos
vaccin
efficaci
vaccin
action
leaki
benefit
threshold
efficaci
nfold
fraction
dose
necessari
reduc
iar
higher
increas
transmiss
intens
figur
occur
leaki
model
infecti
bite
assum
less
like
caus
infect
host
vaccin
probabl
infect
grow
person
receiv
infecti
bite
figur
show
leaki
model
vaccin
action
dose
fraction
much
less
benefici
vaccin
action
leaki
efficaci
modest
r
high
see
appendix
mathemat
detail
recent
studi
suggest
mosquito
bite
rate
individu
age
time
higher
age
perform
sensit
analysi
show
result
unaffect
heterogen
see
hetereogen
bite
rate
appendix
detail
estim
vaccin
coverag
kinshasa
end
june
vaccin
campaign
began
dosespar
strategi
optim
long
fivefold
fraction
vaccin
least
efficaci
figur
base
assumpt
sustain
epidem
transmiss
declin
popul
suscept
host
deplet
primari
analysi
show
dose
fraction
yf
vaccin
loss
efficaci
current
assum
could
provid
substanti
benefit
reduc
attack
rate
yf
popul
consid
assumpt
full
efficaci
fivefold
fraction
like
scenario
despit
lack
efficaci
data
yf
vaccin
sever
reason
two
studi
fiveor
greaterfold
vaccin
dose
shown
indistinguish
immunogen
human
least
prepar
yf
vaccin
substanti
exceed
minimum
standard
potenc
iudos
fraction
level
could
perform
without
drop
threshold
yf
vaccin
live
attenu
viru
biolog
rational
exist
product
vaccineviru
infect
establish
fraction
dose
protect
compar
higher
dose
nonetheless
assess
robust
conclus
dose
fraction
like
benefici
possibl
fact
efficaci
fraction
dose
lower
anticip
consid
possibl
fivefold
fraction
dose
fail
immun
proport
recipi
find
long
least
recipi
fulli
immun
vaccin
peopl
would
immun
vaccin
five
time
mani
peopl
onefifth
dose
populationwid
benefit
higher
coverag
would
outweigh
lower
efficaci
fraction
dose
individu
vaccine
even
unlik
opinion
fraction
dose
would
substanti
less
efficaci
accord
leaki
model
vaccin
individu
imperfectli
protect
infect
infecti
bite
probabl
infect
bite
reduc
vaccin
proport
see
appendix
detail
case
howev
found
especi
hightransmiss
area
fractionateddos
vaccin
would
need
efficaci
provid
benefit
standard
dose
analysi
intend
recommend
extend
coverag
point
knowingli
compromis
efficaci
rather
analysi
indic
strategi
fraction
dose
provid
equival
immunogen
standard
dose
would
greatli
benefici
efficaci
equival
standard
dose
would
still
benefici
unexpectedli
efficaci
somewhat
lower
standard
dose
use
fivefold
fraction
exampl
strategi
best
evid
base
equal
immunogen
howev
data
suggest
fivefold
fraction
could
equal
immunogen
cours
benefit
fraction
would
greater
fivefold
fraction
logist
possibl
compar
efficaci
consid
fraction
dose
resid
area
high
risk
transmiss
anoth
group
interest
travel
must
also
consid
longev
respons
lower
level
exposur
detail
discuss
equiti
outsid
scope
model
paper
cost
fractionaldos
strategi
depend
rout
administr
could
potenti
substanti
less
expens
per
vaccin
recipi
simpl
model
sever
limit
assum
homogen
mix
popul
reason
least
local
vectorborn
diseas
also
fix
particular
valu
r
calcul
assum
valu
maintain
epidem
swept
popul
realiti
r
vari
season
vector
abund
extrins
incub
period
factor
vari
exist
hightransmiss
season
might
enhanc
benefit
fractionaldos
vaccin
importantli
premium
achiev
high
vaccin
coverag
peak
transmiss
maxim
impact
transmiss
limit
suppli
constraint
could
partial
reliev
fraction
howev
casesavert
estim
might
achiev
singl
transmiss
season
season
declin
mosquito
abund
abrog
transmiss
larg
major
popul
becom
infect
focus
benefit
increas
vaccin
coverag
within
singl
popul
given
global
shortag
yf
vaccin
addit
benefit
fraction
dose
extend
coverag
wider
geograph
area
cover
popul
vaccin
could
achiev
standard
dose
inde
part
plan
vaccin
border
area
angola
congo
provid
benefit
popul
well
immun
buffer
slow
movement
diseas
toward
kinshasa
conclud
dose
fraction
could
effect
strategi
improv
coverag
yf
vaccin
reduc
infect
attack
rate
popul
possibl
larg
absolut
rel
margin
high
moder
efficaci
maintain
reduceddos
formul
vaccin
whose
standard
formul
exceed
minimum
concentr
viral
particl
dose
fraction
could
accomplish
without
chang
recommend
particular
plan
use
fraction
dose
extend
coverag
vaccin
within
kinshasa
surround
area
robust
sens
expect
provid
greater
benefit
use
full
dosag
even
counter
current
evid
efficaci
fraction
dose
substanti
lower
standard
dose
rollout
fraction
dose
perhap
preced
accompani
noninferior
studi
intend
vaccin
immunogen
fraction
dose
intend
popul
ongo
program
monitor
observ
studi
safeti
immunogen
possibl
effect
assur
assumpt
underli
rational
program
continu
met
howev
worth
note
fulldos
vaccin
efficaci
inde
nearli
current
believ
estim
rel
efficaci
fraction
vs
standard
dose
compar
studi
would
challeng
imposs
might
case
accru
standarddos
arm
use
wallinga
teuni
method
estim
reproduct
number
cours
yf
outbreak
angola
daili
number
confirm
case
record
april
angola
situat
report
assum
case
attribut
local
transmiss
ie
import
case
let
date
symptom
onset
case
rel
likelihood
case
infect
case
j
w
probabl
densiti
function
serial
interv
assum
probabl
case
j
infect
case
independ
probabl
case
j
infect
case
reproduct
number
case
j
bernoulli
random
variabl
mean
p
ij
reproduct
number
day
name
r
approxim
averag
reproduct
number
case
symptom
onset
day
case
mean
standard
deviat
r
assum
r
normal
distribut
approxim
confid
interv
e
r
z
r
assum
latent
period
incub
period
human
infect
yf
suppos
infect
individu
becom
infecti
time
let
time
infecti
individu
bitten
compet
mosquito
becom
infect
time
mosquito
becom
infecti
time
mosquito
bite
infect
human
host
probabl
distribut
function
serial
interv
calcul
assum
infecti
period
human
exponenti
distribut
mean
day
mosquito
lifespan
exponenti
distribut
mean
vari
week
http
wwwdenguegovsgsubjectasp
assum
extrins
incub
period
follow
weibul
distribut
paramet
exp
temperatur
degre
celsiu
estim
ref
assum
intrins
incub
period
follow
lognorm
distribut
paramet
estim
ref
assum
vaccin
efficaci
nfold
fractionaldos
vaccin
n
increas
linearli
amount
antigen
vaccin
proport
gener
vaccin
efficaci
nfold
fractionaldos
vaccin
n
n
n
increas
linearli
amount
antigen
vaccin
make
assumpt
avoid
overestim
benefit
dose
fraction
allornoth
benefit
threshold
name
n
also
benefit
threshold
ie
n
n
n
fivefold
dose
fraction
benefici
dose
fraction
benefici
fraction
fivefold
reduct
vaccin
efficaci
fraction
increas
like
gradual
assum
given
standard
dose
vaccin
efficaci
appear
close
appendix
figur
illustr
doserespons
relationship
differ
valu
first
provid
mathemat
detail
iar
calcul
case
popul
stratifi
subgroup
vaccin
action
allornoth
iar
fraction
n
denot
iar
n
obtain
solv
equat
r
basic
reproduct
number
initi
proport
popul
suscept
infecti
dose
fraction
reduc
iar
n
n
vaccin
action
leaki
iar
n
obtain
solv
equat
special
case
benefit
threshold
simplifi
next
provid
mathemat
detail
iar
calcul
gener
case
group
let
proport
suscept
infecti
peopl
group
vaccin
campaign
begin
let
v
vaccin
coverag
standarddos
vaccin
group
n
fraction
group
vaccin
coverag
fractionaldos
vaccin
group
v
n
let
expect
number
secondari
infect
group
j
caus
one
infect
group
complet
suscept
popul
vaccin
action
allornoth
groupspecif
iar
obtain
solv
equat
vaccin
action
leaki
groupspecif
iar
obtain
solv
equat
recent
studi
suggest
mosquito
bite
rate
individu
age
time
higher
age
test
robust
result
heterogen
repeat
calcul
figur
use
model
popul
stratifi
age
cutoff
illustr
use
demograph
paramet
angola
around
popul
appendix
figur
show
result
unaffect
heterogen
bite
rate
appendix
tabl
summar
estim
age
distribut
preoutbreak
vaccin
coverag
angola
end
underli
calcul
summar
follow
age
distribut
angola
age
band
obtain
world
factbook
cia
http
wwwciagovlibrarypublicationstheworldfactbookgraph
populationaopopgraph
assum
age
distribut
within
age
band
uniform
routin
yf
vaccin
angola
began
obtain
annual
routin
immun
coverag
among
children
age
month
whounicef
immun
estim
http
appswhointimmunizationmonitor
globalsummaryestim
cago
appendix
tabl
summar
estim
age
distribut
precampaign
vaccin
coverag
kinshasa
end
june
underli
calcul
summar
follow
age
distribut
kinshasa
age
band
obtain
cia
fact
http
wwwciagovlibrarypublicationstheworldfactbookgraphicspopulationcgpopgraph
assum
age
distribut
within
age
band
uniform
yf
vaccin
coverag
kinshasa
end
june
compris
follow
two
compon
routin
yf
childhood
immun
start
obtain
annual
routin
immun
coverag
among
children
age
month
whounicef
immun
estim
http
appswhointimmunizationmonitoringglobalsummaryestim
ccod
assum
routin
immun
coverag
age
month
year
end
june
yf
sever
vaccin
suppli
shortag
emerg
vaccin
around
million
peopl
kinshasa
mayjun
ref
person
commun
bruce
aylward
alejandro
costa
assum
coverag
emerg
vaccin
uniformli
distribut
across
age
plan
deliv
around
million
standarddos
vaccin
kinshasa
vaccin
campaign
julyaugust
person
commun
bruce
aylward
alejandro
costa
target
popul
size
kinshasa
around
million
potenti
million
addit
peopl
adjac
area
million
standarddos
vaccin
administ
children
age
month
year
standard
dose
suffici
vaccin
unvaccin
children
age
rang
rest
vaccin
stockpil
administ
rest
popul
fivefold
fractionaldos
vaccin
consid
altern
age
cutoff
fractionaldos
vaccin
assum
vaccin
stockpil
suffici
vaccin
individu
kinshasa
yet
vaccin
june
consid
allornoth
yf
vaccin
action
mechan
like
leaki
vaccin
action
model
follow
reason
base
limit
evid
immunogen
fraction
dose
date
consid
unlik
reduc
dose
fivefold
perhap
current
prepar
would
result
dramat
lower
efficaci
leaki
type
visual
inspect
data
dose
fraction
trial
vaccin
brazil
show
dose
standard
dose
distribut
serolog
respons
indistinguish
standard
dose
suggest
efficaci
nearli
equival
full
dose
confirm
analysi
peak
viremia
equival
standard
dose
dose
full
dose
fraction
confirm
peak
cytokin
respons
compar
standard
dose
cytokin
test
least
fraction
dose
even
lower
dose
proport
seroconvert
vaccin
lower
observ
full
dose
antibodi
respons
among
seroconvert
appear
similar
dose
data
collect
suggest
approxim
fraction
dose
vaccin
respons
equival
fraction
may
failur
induc
substanti
respons
fraction
recipi
neutral
antibodi
titr
respond
compar
pattern
consist
allornoth
model
search
pubm
googl
scholar
june
term
yellow
fever
vaccin
dose
spare
find
report
random
trial
yellow
fever
yf
vaccin
efficaci
full
lower
dose
three
rel
recent
studi
suggest
similar
immunolog
respons
fivefold
fraction
compar
current
dose
antigen
level
sever
recent
perspect
articl
propos
dosespar
strategi
respons
current
shortag
knowledg
first
studi
test
robust
strategi
term
epidemiolog
impact
uncertainti
surround
fractionaldos
yf
vaccin
efficaci
mode
action
eg
allornoth
leaki
estim
reproduct
number
yf
epidem
angola
studi
first
provid
estim
transmiss
yf
urban
set
character
threshold
vaccin
efficaci
dosespar
drastic
reduc
number
yf
case
show
benefit
dose
fraction
influenc
transmiss
intens
set
target
coverag
fractionaldos
vaccin
efficaci
mode
action
show
dosespar
strategi
kinshasa
vaccin
campaign
julyaugust
robust
effect
strategi
reduc
infect
attack
rate
would
robust
larg
margin
error
case
fivefold
fractionaldos
vaccin
efficaci
turn
lower
expect
result
support
grow
evid
dosespar
strategi
adopt
option
extend
current
spars
yf
vaccin
suppli
epidem
curv
confirm
case
date
symptom
onset
angola
vaccin
coverag
luanda
provinc
achiev
reactiv
yf
vaccin
campaign
start
februari
first
case
yf
outbreak
identifi
luanda
provinc
account
case
confirm
angola
februari
bc
estim
daili
reproduct
number
r
assum
mean
mosquito
lifespan
day
respect
red
data
point
correspond
case
use
estim
initi
reproduct
number
case
symptom
onset
one
mean
serial
interv
vaccin
campaign
began
affect
diseas
transmiss
assum
day
start
campaign
account
time
take
adapt
immun
develop
orang
purpl
horizont
bar
indic
length
mean
mosquito
lifespan
serial
interv
scale
xaxi
respect
assum
whole
popul
suscept
ii
vaccin
action
allornoth
iii
standarddos
vaccin
efficaci
standarddos
vaccin
coverag
v
exce
everyon
popul
vaccin
fivefold
fractionateddos
vaccin
case
fraction
would
n
effect
vaccin
coverag
n
nv
essenti
percentag
popul
immun
function
standarddos
vaccin
coverag
v
standarddos
